Teva Acquires Tourette's Drugmaker For Up To $900M
Biopharmaceutical company Teva Pharmaceuticals, advised by Faegre Drinker Biddle & Reath LLP, on Wednesday announced plans to acquire Bradley Arant Boult Cummings LLP-advised Emalex Biosciences for up to $900 million....To view the full article, register now.
Already a subscriber? Click here to view full article